Sharekhan's research report on PI Industries
Q3FY2021 results were strong with revenues/operating profit of Rs. 1,162 crore/Rs. 276 crore, up by 36.7%/47.7% y-o-y and 9%/14.8% above our estimate of Rs. 1,066 crore/Rs. 240 crore. Revenue beat was driven by a strong outperformance of the CSM business (40.1% y-o-y growth) and domestic business (26.2% y-o-y growth). Strong gross margins and efficient capacity utilisation drove up OPM by 176 bps y-o-y to 23.7%. The management expects strong growth momentum to sustain and guided for revenue growth of 20% each in FY2021 and FY2022. Outlook for CSM business is robust with the likely start of a new MPP in Q4FY21 and launch of 5-6 new molecules in FY22 while strong demand for branded products to drive growth for domestic business.
Outlook
Likely successful deployment of QIP money of Rs. 2,000 crore in high-margin, high-return pharma and specialty chemicals could act as a key re-rating catalyst. Hence, we maintain a Buy on PI Industries with an unchanged PT of Rs. 2,740.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.